Could a simple eye drop shield your cornea during cataract surgery?

NCT ID NCT07694375

Not yet recruiting Prevention Sponsor: Caravel Oculus Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether an investigational eye drop called CA201A can help protect the cornea from cell damage during cataract surgery. About 200 adults in Australia scheduled for cataract surgery will receive either CA201A or a placebo drop four times daily, starting a week before surgery and continuing for four weeks after. Researchers will measure changes in corneal endothelial cell density to see if the treatment preserves eye clarity and health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ascorbic acid ophthalmic solution 5%
What this could lead to: If effective, CA201A could become a simple eye drop that protects the cornea during cataract surgery, reducing the risk of long-term vision problems.
What could go wrong: This is an early-phase trial with only 200 participants, so results may not apply to everyone. The treatment may not work better than placebo, and eye drops can cause irritation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract Corneal Endothelial Cell Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORNEAL ENDOTHELIAL CELL LOSS CORNEAL ENDOTHELIAL DAMAGE FOLLOWING THE HARD NUCLEAR CATARACT SURGERY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.